CHIARLE, Roberto
Dettaglio
CHIARLE, Roberto
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
Pubblicazioni
Risultati 1 - 20 di 150 (tempo di esecuzione: 0.0 secondi).
Titolo | Data di pubblicazione | Autore(i) | |
---|---|---|---|
1 | Ablation of oncogenic ALK is a viable therapeutic approach fAblation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas | 2006 | PIVA R; CHIARLE R; MANAZZA AD; TAULLI R; SIMMONS W; AMBROGIO C; D'ESCAMARD V; PELLEGRINO E; PONZETTO C; PALESTRO G; INGHIRAMI G |
2 | Advances in cancer immunology and cancer immunotherapy | 2016 | Voena, Claudia*; Chiarle, Roberto |
3 | ALK inhibitors and vaccination against anaplastic lymphoma kinase (ALK) induce potent anti-tumor activity improving survival in non small cell lung carcinoma (NSCLC) | 2012 | C. Voena; M. Menotti; C. Mastini; F. Di Giacomo; D.L. Longo; C. Martinengo; S. Aime; F. Cavallo; G. Inghirami; R. Chiarle |
4 | ALK protein tyrosine kinase, cells and methods embodying and using same | 2005 | R. Chiarle; G. Inghirami |
5 | ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis | 2014 | Martinengo, Cinzia; Poggio, Teresa; Menotti, Matteo; Scalzo, Maria Stella; Mastini, Cristina; Ambrogio, Chiara; Pellegrino, Elisa; Riera, Ludovica; Piva, Roberto; Ribatti, Domenico; Pastorino, Fabio; Perri, Patrizia; Ponzoni, Mirco; Wang, Qi; Voena, Claudia; Chiarle, Roberto |
6 | An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors | 2008 | P. ACCORNERO; G. LATTANZIO; T. MANGANO; R. CHIARLE; R. TAULLI; F. BERSANI; P.E. FORNI; S. MIRETTI; C. SCUOPPO; W. DASTRU; J. CHRISTENSEN; T. CREPALDI; C. PONZETTO |
7 | Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? | 2009 | Fornari A; Piva R; Chiarle R; Novero D; Inghirami G |
8 | Anaplastic large-cell lymphoma | 2011 | Inghirami G; Pileri SA; Chiarle R; Cuccuru G; Martinoglio B; Medico E; Pellegrino E; Piva R; Ruberto ML; Fornari A; Novero D; Chilosi M; Zamó A; Facchetti F; Lonardi S; De Chiara A; Fulciniti F; Doglioni C; Ponzoni M; Agnelli L; Neri A; Todoerti K; Agostinelli C; Piccaluga PP; Falini B; Tiacci E; Van Loo P; Tousseyn T; De Wolf-Peeters C; Geissinger E; Muller-Hermelink HK; Rosenwald A; Piris MA; Rodriguez ME. |
9 | Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death | 2002 | ZAMO A; R. CHIARLE; PIVA R; HOWES J; FAN Y; CHILOSI M; LEVY DE; INGHIRAMI G. |
10 | The anaplastic lymphoma kinase as an oncogene in solid tumors | 2015 | Voena, Claudia; Peola, Silvia; Chiarle, Roberto |
11 | Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination | 2007 | R. Chiarle; G. Inghirami; G. Forni |
12 | Anaplastic lymphoma kinase: an oncogene for tumor vaccination | 2009 | Mastini C; Martinengo C; Inghirami G; Chiarle R. |
13 | Argyrophilic nucleolar organizer region counts predict survival in thymoma. | 1994 | PICH A ;CHIARLE R ;CHIUSA L ;PALESTRO G |
14 | Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. | 2013 | Capello M; Cappello P; Linty FC; Chiarle R; Sperduti I; Novarino A; Salacone P; Mandili G; Naccarati A; Sacerdote C; Beghelli S; Bersani S; Barbi S; Bassi C; Scarpa A; Nisticò P; Giovarelli M; Vineis P; Milella M; Novelli F. |
15 | Autoantibody signature in human ductal pancreatic adenocarcinoma | 2007 | TOMAINO B; CAPPELLO P; CAPELLO M; FREDOLINI C; PONZETTO A; NOVARINO A; CIUFFREDA L; BERTETTO O; ANGELIS CD; GAIA E; SALACONE P; MILELLA M; NISTICO P; ALESSIO M; CHIARLE R; GIUFFRIDA MG; GIOVARELLI M; NOVELLI F |
16 | BRAF gene is not mutated in plasma cell leukemia and multiple myeloma | 2003 | BONELLO L; VOENA C; LADETTO M; BOCCADORO M; PALESTRO G; INGHIRAMI G; R. CHIARLE |
17 | A Braf kinase-inactive mutant induces lung adenocarcinoma | 2017 | Nieto P.; Ambrogio C.; Esteban-Burgos L.; Gomez-Lopez G.; Blasco M.T.; Yao Z.; Marais R.; Rosen N.; Chiarle R.; Pisano D.G.; Barbacid M.; Santamaria D. |
18 | The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo | 2015 | Karreth, Florian A; Reschke, Markus; Ruocco, Anna; Ng, Christopher; Chapuy, Bjoern; Léopold, Valentine; Sjoberg, Marcela; Keane, Thomas M; Verma, Akanksha; Ala, Ugo; Tay, Yvonne; Wu, David; Seitzer, Nina; Velasco-Herrera, Martin Del Castillo; Bothmer, Anne; Fung, Jacqueline; Langellotto, Fernanda; Rodig, Scott J; Elemento, Olivier; Shipp, Margaret A; Adams, David J; Chiarle, Roberto; Pandolfi, Pier Paolo |
19 | Calming down T cell acute leukemia. | 2012 | Hirsch E;Chiarle R |
20 | CD30 expression in anaplastic large cell lymphomas is dependent on ALK tyrosine kinase activity via Stat3 phosphorylation and JunB upregulation | 2005 | Boccalatte F; Piva R; Manazza A; Palestro G; Chiarle R; Inghirami G |